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SELECTION OF THE MONTH 
Big title: Plasma exchange improves survival of Acute Liver Failure patients 
 
Small Titles: Maternal exercise during pregnancy protects from hepatic 
steatosis in mice, Secretion of infectious hepatitis E virus in urine 
 
LIVER INJURY 
TRAF3 and NK cells in hepatic ischemia/reperfusion injury 
Hepatic ischemia/reperfusion (I/R) injury that includes cell death and inflammation 
complicates diverse surgical procedures, such as liver transplantation. In this issue of 
the Journal two articles provide new insights into mechanisms that promote hepatic 
I/R injury or conversely protect the liver against this injury. Hu et al. show that the 
protein TRAF3 (TNF receptor associated factor 3) promotes liver damage and 
inflammation via TAK 1 (TGF-β-activated kinase 1)-dependent activation of the 
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mitogen-activated protein kinase and IκB kinase pathways. These findings identify 
targets for novel therapeutic approaches. Eggenhofer et al. investigated the role 
retinoic acid receptor-related orphan nuclear receptor (RORɣT)-expressing, IL-22-
producing NKp46+ cells (NK22) which are unconventional subsets of NK cells. They 
show that RORɣT-expressing NK22 play a crucial protective role against hepatic 
I/R injury in mice.  
 
LIVER FIBROSIS 
Role of Hic-5 and age 
TGF-β (transforming-growth factor β) is a key stimulus for hepatic stellate cell 
activation and production of extracellular matrix (ECM) component. Hic-5 (hydrogen 
peroxide-inducible clone-5), also known as Tgfb1i1 (TGF-β1-induced transcript 1 
protein), is a TGF-β-target gene whose function is elusive. Using models of fibrosis in 
wild-type and Hic-5 KO mice, Lei et al. now show that Hic-5 deficiency attenuates 
the activation of HSCs and liver fibrosis though reducing the TGF-β/Smad2 
signaling by upregulation of Smad7. Therefore, inhibition of HIC-5 might be beneficial 
for treating liver fibrosis. 
Little is known on the impact of age on ECM turn-over. Karsdal et al. addressed this 
question by investigating ECM fragments in serum of rats aging from 1 to 12 months. 
They show here that ECM turnover rates were consistently different in young vs old 
animals, up to 30 fold. This appears to be due to body growth, a different ECM 
composition and a higher regenerative capability of connective tissues in young 
versus old animals. These findings should be considered when developing 
diagnostic and therapeutic biomarkers of fibrosis based on serum levels of 
ECM fragments. 
 
INFLAMMATORY HEPATOCELLULAR ADENOMAS 
Protective role of Nrf2 and p65 
Hepatocyte homeostasis is frequently challenged by overproduced oxygen reactive 
species. The resulting oxidative stress induces a cell-autonomous (intrinsic) response 
aimed to restore cell homeostasis. Nrf2 (encoded by Nfe2l2) is a transcription factor 
of the bZIP family which is induced by oxidative stress. It binds to antioxidant 
response (ARE) elements in the promoter regions of target genes and plays a crucial 
role in the restoration of homeostasis in response to oxidative stress. Khöler et al. 
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were interested in the cross-talk of Nrf2 and NF-κB/p65 (encoded by RelA) and 
investigated mice KO for both Nfe2l2 and RelA. They show that the double mutant 
female mice develop benign liver tumors that are inflammatory recapitulating human 
inflammatory hepatocellular adenomas. They also find a functional cross-talk of 
Nrf2 and NF-κB/RelA in hepatocytes, which plays an important homeostatic 
role by protecting the liver from necrosis, inflammation and fibrosis. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Preoperative HVPG  
Predicting post-hepatectomy liver failure in patients undergoing liver resection for 
HCC is not easy. It has been suggested that a pre-operative HVPG (hepatic venous 
pressure gradient) of 10 mm Hg or more may be associated with a significant risk of 
post-hepatectomy liver failure. However, Cucchetti et al. show that if the value of 
pre-operative HVPG can be used before surgery to stratify the risk of post-
hepatectomy liver failure, the proposed cut-off of 10 mm Hg excludes 
approximately 25% of the patients who otherwise would benefit from surgery 
without short to mid-term postoperative sequelae. 
 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Gestational and risk of steatosis in mice, chemokines regulate inflammation in 
steatohepatitis 
Maternal exercise confers protection to adult offspring against various diseases, but 
its influence on the development of liver diseases is largely unknown. In this issue, 
Sheldon et al. investigates if maternal exercise during gestation would reduce high 
fat diet induced hepatic steatosis in adult rat offspring. The authors convincingly 
demonstrate that offspring mice from mothers that exercise during pregnancy that 
were fed with a high fat diet had reduced body fat, better glucose tolerance and less 
hepatic steatosis. These beneficial effects were associated with increased markers 
of hepatic mitochondrial biogenesis and hepatic triacylglycerol secretion. This 
important experimental study, which should be confirmed in epidemiological studies, 
reinforces recent research published in the Journal indicating that exercise has 
protective effects against fatty liver diseases.  
CXC chemokines are chimio-attractants for neutrophils, which typically infiltrate the 
livers from patients with non-alcoholic steatohepatitis (NASH). In this issue, Zhang et 
4 
 
al. performed a translational study using human samples as well as mice with genetic 
and/or pharmacological blockade of the CXC3 receptor. The authors found that 
CXCR3 was significantly up-regulated in liver tissues of patients with NASH and that 
Cxcr3-/- mice were more resistant to diet-induced steatohepatitis. Importantly, 
Cxcr3 activation mediated autophagosome-lysosome impairment and endoplasmic 
reticulum stress in experimental NASH. These intriguing results suggest that 
targeting CXC chemokines could be an appealing strategy to treat steatohepatitis in 
humans. The main concern of this approach is that CXC chemokines are essential 
for defense against bacterial infections. Further studies should explore whether this 
approach is safe when administered for prolonged periods of time. 
 
HEPATITIS C 
Better is the enemy of good – MALACHITE Phase IIIb trial: The last gem of the 
puzzle, new concepts in HCV-induced alterations of lipid metabolism 
The advantages of the current interferon-free direct acting antiviral (DAA) regimens 
with respect to their safety and efficacy in comparison to the previous DAA-based 
triple regimens including peg-interferon (IFNa) plus ribavirin (RBV) have never been 
demonstrated by direct comparison in a randomized fashion. In two open-label, 
phase 3b trials Dore et al. compared safety and efficacy of all-oral 
ombitasvir/paritaprevir/ritonavir and dasabuvir+/- RBV and telaprevir-based triple 
peg-IFNa plus RBV regimen in treatment-naïve (MALACHITE-I) or -experienced 
(MALACHITE-II) non-cirrhotic patients with hepatitis C virus (HCV) type 1 infection. 
Among treatment-naïve patients SVR rates with IFNa-free versus triple regimen were 
97% and 80%, and among experienced patients 99% and 66%. A striking 
difference was also observed concerning patient-reported outcomes, 
premature treatment discontinuation and severe adverse events also favoring 
the interferon-free regimen. Is there any reason to further consider interferon-based 
regimens? The answer from the gem study is no. 
HCV highjacks lipid metabolism pathway for proper viral replication leading to 
dyslipidemia, reduced serum cholesterol levels and hepatic steatosis – a hallmark of 
HCV type 3 infection – but also modifications of antiviral treatment response. The 
aims of the elegant study by Younossi et al. were to assess HCV type-specific 
changes in serum lipids and sterol metabolites in HCV type 2 and 3 infections based 
on disease severity and response to treatment with sofosbuvir and ribavirin. 
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Reduced de novo lipogenesis resulting in relative hypocholesterolemia was 
observed in HCV type 3 infection due to either disturbance in the distal cholesterol 
biosynthesis pathway, or a selective derangement of hepatocyte lipid secretion 
which, however, can be restored by sofosbuvir-induced suppression of viral 
replication. This study provides new insights into the selective dysregulation of post-
squalene sterol and lipid metabolism in chronic HCV infection. 
 
HEPATITIS E 
Secretion of infectious hepatitis E virus in urine 
Hepatitis E virus (HEV) mainly replicates in the liver but a broader organ tropism of 
HEV have been demonstrated in recent animal studies including small intestines, 
lymph nodes, colon, brain, and kidneys, and this might be an explanation for the 
significant number of extrahepatic manifestations which have been linked to this 
infection. The study by Geng et al. described for the first time the detection of 
HEV RNA and HEV antigen in the urine of patients with acute and persistent 
HEV infection and the infectivity of urine-derived HEV was proven by 
inoculation studies in monkeys. The study provides not only new insides into the 
mechanisms of HEV replication, and the dynamics of HEV dissemination but also 
implicates that HEV-Ag testing in urine may become a useful new marker for the 
diagnosis of hepatitis E viremia. 
 
ACUTE LIVER FAILURE & LIVER REGENERATION 
Plasma exchange improves survival of ALF patients and liver derived 
exosomes can improve hepatic regeneration 
Despite improvements in our understanding of acute liver failure, mortality of patients 
without liver transplantation remains unacceptably high. The study of Larsen et al. 
describes the results of a landmark randomized clinical trial that took over 10-years to 
perform and shows that treatment with plasma exchange can improve the 
survival of ALF patients, providing proof of concept for ‘detoxification’ systems.  
Also, in the present issue, an exciting paper by Nojima et al. suggests that 
exosomes derived from hepatocytes but not other cell types can enhance liver 
regeneration in vitro and in vivo in animal models. Their data suggests that the 
operative mechanism is through hepatic transfer of sphingosine kinase 2, which 
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increases the synthesis of sphingosine-1-phosphate within the target hepatocyte 
providing a translatable strategy. 
 
CIRRHOSIS 
NF-κB-induced STS may cause feminization to limit inflammation; hepatic 
tissue factor mediates hypercoagulable state in cirrhosis 
The exact mechanism of feminization in cirrhosis is unclear and the role of elevated 
estrogens in regulating inflammation is unknown. Xie et al. show that STS (encoding 
steroid sulfatase) is a novel NF-κB target gene that is induced in the liver of patients 
with cirrhosis. Their data strongly suggest that the inflammatory induction of 
STS may be the cause of estrogen excess in chronic liver disease. They 
hypothesize that this estrogen may also regulate hepatic inflammation through a 
negative feedback mechanism. 
Mechanisms of coagulation disturbances in cirrhosis are unclear as many studies 
suggest that despite increased prothrombin time, the patients are hypercoagulable. A 
very important paper in animal models by Rautou et al. showed incontrovertibly 
the importance of hepatic ‘tissue factor’ (TF) as being important in mediating 
the hypercoagulable state observed in these animals. Knocking out hepatic but 
not myeloid TF prevented this hypercoagulable state. 
 
